A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)
Latest Information Update: 05 May 2022
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
- Indications Acute coronary syndromes; Cardiovascular disorders; Stroke; Unstable angina pectoris
- Focus Registrational; Therapeutic Use
- Acronyms IMPROVE-IT
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough
- 12 Oct 2021 Results assessing the relationship between baseline LDL-C above and below 70 mg/dL and the benefit of adding ezetimibe to statin in patients post-acute coronary syndrome (ACS), published in the Journal of the American College of Cardiology.
- 27 Aug 2019 Results assessing the role of established CV biomarkers in assessing likely benefit with Ezetimibe added to statin therapy in post-ACS patients in the biomarker substudy, published in the Journal of the American College of Cardiology
- 25 Jan 2019 Results published in the American Journal of Cardiology